CytoSorb Information
SIRS and SEPSIS. Regain control CytoSorb Therapy SIRS and SEPSIS. Regain control. • Proprietary polymer–technology effectively lowers systemic cytokine levels • First-in-class cytokine adsorber with CE approval • Works with standard hospital CRRT or dialysis equipment • Setup in minutes and easy to use Elevation of cytokines Pro-inflammatory CytoSorb as adjunctive therapy in SIRS and SEPSIS: Anti-inflammatory • Reduces cytokine burden by direct cytokine removal and decreasing cytokine production Toxic level rgan o Multi- Organ-p failure Death • Improves hemodynamics and has organ-protective effects rotectiv Insult Use of C ytoSorb CytoSorbents Europe GmbH Bölschestr. 116 12587 Berlin, Germany e effects • Stabilizes patients during cytokine storm and bridges life threatening situations Recovery with CytoSorb office + 49 30 654 99 145 fax + 49 30 654 99 146 [email protected] • Buys time for infectious focus identification and surgical control www.cytosorb-therapy.com Intelligent polymer-technology • Hightech-polymer • Size selectivity < 55kD • Low flow resistance • 120 ml blood volume/filling volume • Pre-filled with 0.9 % sodium chloride Section through Adsorber Hemoperfusion Adsorber bead Inner structure • Gamma-sterilized, storable for 3 years Safety through selectivity • Whole blood perfusion – no plasma separation necessary • Compatible with almost all renal replacement systems or blood pumps (no additional capital costs) • Applicable alone as hemoperfusion or in combination with a dialysis filter (all RRT modes) • Integratable into cardiopulmonary bypass systems • Anticoagulation as usual (heparin or citrate) • No additional circulation, machines or cells necessary Setup within minutes and easy to use Hemoperfusion CytoSorbents Europe GmbH Bölschestraße 116 12587 Berlin, Germany Renal Replacement office + 49 30 654 99 145 fax + 49 30 654 99 146 [email protected] Cardiopulmonary Bypass www.cytosorb-therapy.com 80-001/2.0
© Copyright 2024